Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Short term Debt: 2022-2025

Historic Short term Debt for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $44.4 million.

  • NewAmsterdam Pharma Co N.V's Short term Debt rose 134.70% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 134.70%. This contributed to the annual value of $37.5 million for FY2024, which is 198.35% up from last year.
  • NewAmsterdam Pharma Co N.V's Short term Debt amounted to $44.4 million in Q3 2025, which was up 111.93% from $20.9 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's Short term Debt's 5-year high stood at $44.4 million during Q3 2025, with a 5-year trough of $7,727 in Q2 2023.
  • Its 3-year average for Short term Debt is $23.8 million, with a median of $23.5 million in 2025.
  • Its Short term Debt has fluctuated over the past 5 years, first soared by 304,610.75% in 2024, then dropped by 28.85% in 2025.
  • Quarterly analysis of 4 years shows NewAmsterdam Pharma Co N.V's Short term Debt stood at $4.1 million in 2022, then surged by 203.21% to $12.6 million in 2023, then soared by 198.35% to $37.5 million in 2024, then spiked by 134.70% to $44.4 million in 2025.
  • Its Short term Debt stands at $44.4 million for Q3 2025, versus $20.9 million for Q2 2025 and $23.5 million for Q1 2025.